BACKGROUND: Calcineurin inhibitor (CNI)-induced thrombotic microangiopathy (TMA) is a rare complication after renal transplantation. It may be difficult to distinguish from CNI toxicity and acute antibody-mediated rejection (AMR). Its clinical presentation may vary from isolated localised forms up to catastrophic systemic presentations. CASE: We report a case of tacrolimus-induced TMA soon after renal transplantation in an 11-year-old boy who received his second renal transplantation. His first graft was lost because of AMR. On day 12 after his second renal transplantation, his renal function started worsening and a kidney biopsy was performed, which showed histopathological signs of TMA. The diagnosis of tacrolimus-induced TMA was established after excluding AMR and other causes of de novo TMA. Genetic complement investigation disclosed two complement factor H risk polymorphisms as possible modifiers of TMA emergence. Treatment was based on replacing tacrolimus with everolimus, with a subsequent normalisation of renal function. CONCLUSION: A prompt diagnosis of de novo TMA by early allograft biopsy is essential for the allograft outcome and genetic investigations for possible complement abnormalities are reasonable, not only for patients with a systemic aspect of their post-transplant TMA. Replacing tacrolimus with everolimus effectively controlled the TMA and stabilised renal function in our patient.
BACKGROUND:Calcineurin inhibitor (CNI)-induced thrombotic microangiopathy (TMA) is a rare complication after renal transplantation. It may be difficult to distinguish from CNI toxicity and acute antibody-mediated rejection (AMR). Its clinical presentation may vary from isolated localised forms up to catastrophic systemic presentations. CASE: We report a case of tacrolimus-induced TMA soon after renal transplantation in an 11-year-old boy who received his second renal transplantation. His first graft was lost because of AMR. On day 12 after his second renal transplantation, his renal function started worsening and a kidney biopsy was performed, which showed histopathological signs of TMA. The diagnosis of tacrolimus-induced TMA was established after excluding AMR and other causes of de novo TMA. Genetic complement investigation disclosed two complement factor H risk polymorphisms as possible modifiers of TMA emergence. Treatment was based on replacing tacrolimus with everolimus, with a subsequent normalisation of renal function. CONCLUSION: A prompt diagnosis of de novo TMA by early allograft biopsy is essential for the allograft outcome and genetic investigations for possible complement abnormalities are reasonable, not only for patients with a systemic aspect of their post-transplant TMA. Replacing tacrolimus with everolimus effectively controlled the TMA and stabilised renal function in our patient.
Authors: M A Abrera-Abeleda; C Nishimura; J L H Smith; S Sethi; J L McRae; B F Murphy; G Silvestri; C Skerka; M Józsi; P F Zipfel; G S Hageman; R J H Smith Journal: J Med Genet Date: 2005-11-18 Impact factor: 6.318
Authors: D Noone; J Al-Matrafi; K Tinckam; P F Zipfel; A M Herzenberg; P S Thorner; F G Pluthero; W H A Kahr; G Filler; D Hebert; E Harvey; C Licht Journal: Am J Transplant Date: 2012-06-08 Impact factor: 8.086
Authors: A A Satoskar; R Pelletier; P Adams; G M Nadasdy; S Brodsky; T Pesavento; M Henry; T Nadasdy Journal: Am J Transplant Date: 2010-08 Impact factor: 8.086
Authors: Shane M Meehan; Joseph Kremer; Farah N Ali; Jessica Curley; Susana Marino; Anthony Chang; Pradeep V Kadambi Journal: Clin J Am Soc Nephrol Date: 2010-10-21 Impact factor: 8.237
Authors: H P H Neumann; M Salzmann; B Bohnert-Iwan; T Mannuelian; C Skerka; D Lenk; B U Bender; M Cybulla; P Riegler; A Königsrainer; U Neyer; A Bock; U Widmer; D A Male; G Franke; P F Zipfel Journal: J Med Genet Date: 2003-09 Impact factor: 6.318
Authors: Joshua Schwimmer; Tibor A Nadasdy; Patrice F Spitalnik; Karen L Kaplan; Martin S Zand Journal: Am J Kidney Dis Date: 2003-02 Impact factor: 8.860